Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NicVAX vaccine · 1 trial · 1 indication
QoL and health utilization questionnaires will be used to measure this outcome.
| Arm | Type | Description |
|---|---|---|
| NicVAX | EXPERIMENTAL | Experimental vaccine |
| Placebo | PLACEBO_COMPARATOR | Placebo vaccine |
| Name | Type | Description |
|---|---|---|
| NicVAX vaccine | BIOLOGICAL | NicVAX vaccine given 6 times over 6 months |
| Placebo | BIOLOGICAL | Placebo vaccine given 6 times over 6 months |
Inclusion Criteria: * Subjects who are eligible for randomization or have not reached Week 12 in Nabi-4514 or Nabi-4515 studies. * Subjects who agree to participate in health-related quality of life study. Exclusion Criteria: * Subjects who are unable to complete a HRQoL questionnaire because of ...
NicVAX vaccine is an investigational monoclonal antibody being developed for smoking cessation. It is designed to help people quit smoking, and it is being studied in the context of psychiatric care. The drug is still in clinical development and has not been approved by the FDA.
NicVAX vaccine is being developed by GSK plc, which trades under the ticker GSK. The company is conducting clinical trials to evaluate the vaccine's safety and efficacy for smoking cessation.
NicVAX vaccine is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug is not currently in active trials.
NicVAX vaccine has one completed Phase 3 clinical trial, identified as NCT01178346. This trial, titled 'Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies,' enrolled 500 participants in the United States and focused on smoking cessation.
Yes, NicVAX vaccine is classified as a monoclonal antibody. It is being investigated as a potential treatment to aid smoking cessation, and it is administered as a vaccine to elicit an immune response.